⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TRAX News
First Tracks Biotherapeutics, Inc. Ordinary Shares
Form 8-K
sec.gov
TRAX
Form 8-K
sec.gov
TRAX
First Tracks Biotherapeutics Announces $200 Million Private Placement
globenewswire.com
TRAX
Form 8-K
sec.gov
TRAX
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
globenewswire.com
TRAX
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
globenewswire.com
TRAX
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
globenewswire.com
TRAX
Form 8-K
sec.gov
TRAX
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
TRAX
Form 8-K
sec.gov
TRAX